Biochemical Recurrence of Prostate Cancer: Initial Results with [¹⁸F]PSMA-1007 PET/CT

Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. 68 Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several 18 F-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of 18 F-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of 18 F-PSMA-1007. Results: 18 F-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in 18 F-PSMA-1007-positive lesions 1 and 3 h after injection (median SUV max , 7.00 vs. 11.34; P , 0.001; n 5 76). Fortyfour (88%) of 50 18 F-PSMA-1007-positive lymph nodes had a shortaxis diameter of less than 8 mm. Conclusion: In this pilot study, 18 F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.